GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Total Liabilities

Pharming Group (CHIX:PHARMA) Total Liabilities : €223.8 Mil (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Pharming Group Total Liabilities?

Pharming Group's Total Liabilities for the quarter that ended in Dec. 2023 was €223.8 Mil.

Pharming Group's quarterly Total Liabilities increased from Jun. 2023 (€211.77 Mil) to Sep. 2023 (€212.25 Mil) and increased from Sep. 2023 (€212.25 Mil) to Dec. 2023 (€223.82 Mil).

Pharming Group's annual Total Liabilities increased from Dec. 2021 (€180.89 Mil) to Dec. 2022 (€208.77 Mil) and increased from Dec. 2022 (€208.77 Mil) to Dec. 2023 (€223.82 Mil).


Pharming Group Total Liabilities Historical Data

The historical data trend for Pharming Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Total Liabilities Chart

Pharming Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.67 193.19 180.89 208.77 223.82

Pharming Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 208.77 208.89 211.77 212.25 223.82

Pharming Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pharming Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=71.497+(152.318+-2.8421709430404E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=223.8

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=424.437-200.622
=223.8

Pharming Group's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=71.497+(152.318+-2.8421709430404E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=223.8

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=424.437-200.622
=223.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharming Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pharming Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group (CHIX:PHARMA) Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.

Pharming Group (CHIX:PHARMA) Headlines

No Headlines